At 49, She Got Her PhD to Help Her Son With Angelman. Now, She Created COMBINEDBrain To Help Many Related Rare Diseases.

As originally reported in Angelman Syndrome News, Terry Jo Bichell is a PhD researcher, former director and scientific officer of the Angelman Biomarkers and Outcomes Measures Alliance and Tennessee's ambassador…

Continue Reading At 49, She Got Her PhD to Help Her Son With Angelman. Now, She Created COMBINEDBrain To Help Many Related Rare Diseases.
These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies
EliasSch / Pixabay

These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies

According to a story from BioSpace, the gene therapy companies Sarepta Therapeutics, Inc. and StrideBio, Inc. have recently announced the completion of a licensing and collaboration agreement that could lead…

Continue Reading These Two Companies Just Announced a Partnership to Develop Multiple Gene Therapies

Gene Therapy for 12 Rare Diseases will be Investigated Thanks to this Industry-Academia Partnership

Extended Collaboration  Amicus Therapeutics has just announced that they are expanding their collaboration with the University of Pennsylvania's Perelman School of Medicine for the next five years. This collaboration is…

Continue Reading Gene Therapy for 12 Rare Diseases will be Investigated Thanks to this Industry-Academia Partnership

New Technology for Diagnosing Rare Conditions by Photograph May Foster Employment Discrimination?

As discussed in a recent article on PatientWorthy the FDNA has recently developed a new kind of algorithm which can diagnose rare genetic conditions such as Angelman syndrome, Williams syndrome, and Fragile X syndrome using…

Continue Reading New Technology for Diagnosing Rare Conditions by Photograph May Foster Employment Discrimination?
Angelman Syndrome Clinic Network is Now International
https://pixabay.com/en/hands-world-map-global-earth-600497/

Angelman Syndrome Clinic Network is Now International

Angelman Syndrome (AS) is a neurogenetic disorder. It's not fatal, but prevents patients' from living independently. It causes neurological impairment, seizures, and balance issues among other problems. It's caused by a…

Continue Reading Angelman Syndrome Clinic Network is Now International

A Recent Study Has Found That Minocycline Doesn’t Benefit People with Angelman Syndrome

The drug minocycline is a tetracycline antibiotic. Previous research using mouse models has indicated that it may have anti-inflammatory and antiapoptotic (prevents cell death) properties and may benefit some neurological…

Continue Reading A Recent Study Has Found That Minocycline Doesn’t Benefit People with Angelman Syndrome
Angelman Syndrome Treatment Being Developed is Awarded ‘Orphan Drug’ Status in the U.S.
Source: Pixabay

Angelman Syndrome Treatment Being Developed is Awarded ‘Orphan Drug’ Status in the U.S.

A new drug being developed to treat Angelman syndrome (AS) has just been approved for ‘orphan drug’ status in the U.S., reports GlobeNewswire. The drug, called GTX-101, works by activating the…

Continue Reading Angelman Syndrome Treatment Being Developed is Awarded ‘Orphan Drug’ Status in the U.S.
An Experimental Treatment for Fragile X and Angelman Syndromes Gets Fast Track Designation
Source: Pixabay

An Experimental Treatment for Fragile X and Angelman Syndromes Gets Fast Track Designation

According to a story from pharmiweb.com, the pharmaceutical company Ovid Therapeutics announced recently that the U.S. Food and Drug Administration (FDA) has given its drug candidate OV101 Fast Track designation…

Continue Reading An Experimental Treatment for Fragile X and Angelman Syndromes Gets Fast Track Designation
The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials
vitalworks / Pixabay

The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials

According to a story from Charcot-Marie-Tooth Disease News, the U.S. Food and Drug Administration (FDA), under the leadership of commissioner Scott Gottlieb, has begun to change clinical trials by accepting…

Continue Reading The FDA is Beginning to Accept New Endpoints and “Real World” Data in Clinical Trials